Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy.
Guarneri V, Pronzato P, Bertetto O, Roila F, Amunni G, Bortolami A, Tognazzo S, Griguolo G, Pagano E, Stracci F, Bianconi F, Gemmi F, Bachini L, Ciccone G, Paoli G, Paleari L, Conte PF; Periplo Association. Guarneri V, et al. Among authors: bertetto o. JCO Oncol Pract. 2020 Feb;16(2):e211-e220. doi: 10.1200/JOP.19.00466. Epub 2019 Dec 19. JCO Oncol Pract. 2020. PMID: 31855497 Free PMC article.
Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART).
Ricardi U, Racca P, Franco P, Munoz F, Fanchini L, Rondi N, Dongiovanni V, Gabriele P, Cassoni P, Ciuffreda L, Morino M, Filippi AR, Aglietta M, Bertetto O. Ricardi U, et al. Among authors: bertetto o. Med Oncol. 2013;30(2):581. doi: 10.1007/s12032-013-0581-0. Epub 2013 Apr 19. Med Oncol. 2013. PMID: 23606239 Clinical Trial.
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Guarneri V, Frassoldati A, Bruzzi P, D'Amico R, Belfiglio M, Molino A, Bertetto O, Cascinu S, Cognetti F, Di Leo A, Pronzato P, Crinó L, Agostara B, Conte P. Guarneri V, et al. Among authors: bertetto o. Clin Breast Cancer. 2008 Oct;8(5):453-6. doi: 10.3816/CBC.2008.n.056. Clin Breast Cancer. 2008. PMID: 18952561 Clinical Trial.
[Adapting clinical practice guidelines to a regional oncology network: the Piedmont experience].
Gelormino E, Pagano E, Appiano S, Ceccarelli M, Ciuffreda L, Comandone A, Farina E, Merletti F, Mussa A, Penna A, Ponti A, Raciti I, Scagliotti GV, Segnan N, Senore C, Sismondi P, Vineis P, Bertetto O, Ciccone G. Gelormino E, et al. Among authors: bertetto o. Epidemiol Prev. 2007 Jan-Feb;31(1):25-33. Epidemiol Prev. 2007. PMID: 17591401 Free article. Italian.
Variability of clinical target volume delineation for rectal cancer patients planned for neoadjuvant radiotherapy with the aid of the platform Anatom-e.
Franco P, Arcadipane F, Trino E, Gallio E, Martini S, Iorio GC, Piva C, Moretto F, Ruo Redda MG, Verna R, Tseroni V, Bona C, Pozzi G, Fiandra C, Ragona R, Bertetto O, Ricardi U. Franco P, et al. Among authors: bertetto o. Clin Transl Radiat Oncol. 2018 Jun 11;11:33-39. doi: 10.1016/j.ctro.2018.06.002. eCollection 2018 Jun. Clin Transl Radiat Oncol. 2018. PMID: 29928706 Free PMC article.
Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
Berruti A, Fara E, Tucci M, Tarabuzzi R, Mosca A, Terrone C, Gorzegno G, Fasolis G, Tampellini M, Porpiglia F, De Stefanis M, Fontana D, Bertetto O, Dogliotti L; Gruppo Onco-Urologico Piemontese, Rete Oncologica Piemontese. Berruti A, et al. Among authors: bertetto o. Urol Oncol. 2005 Jan-Feb;23(1):1-7. doi: 10.1016/j.urolonc.2004.06.003. Urol Oncol. 2005. PMID: 15885575 Clinical Trial.
108 results